18F-FDG PET 显像的颈动脉斑块炎症与早期复发性卒中风险
多中心前瞻性队列 BIOVASC 纳入颈动脉狭窄且近期卒中/TIA 患者,用 18F-FDG PET/CTA 测斑块 SUVmax 并随访 90 天,校正后每 1 g/mL SUVmax 复发性卒中风险比 2.2(CI 1.1-4.5;P=0.025)。与 Dublin 和 Barcelona 研究个体数据合并(n=196)后,全校正任何复发性卒中风险比 2.19(CI 1.41-3.39;P<0.001),PET 后复发性卒中风险比 4.57(CI 1.5-13.96;P=0.008)。
要点
- 颈动脉斑块 18F-FDG 摄取独立预测 PET 后复发性卒中。
- BIOVASC 中每 1 g/mL SUVmax 复发性卒中风险比 2.2(CI 1.1-4.5)。
- 合并队列中 PET 后复发性卒中风险比 4.57(CI 1.5-13.96)。
核心结论
- 斑块炎症相关 18F-FDG 摄取独立预测 PET 后未来复发性卒中。
研究设计与样本
- 多中心前瞻性队列 BIOVASC 纳入颈动脉狭窄且近期卒中/TIA 患者,随访 90 天。
- 系统综述同类研究并合并 Dublin 和 Barcelona 两独立研究的未发表个体患者数据。
主要发现
- BIOVASC(n=109,14 例复发性卒中)校正后每 1 g/mL SUVmax 复发性卒中风险比 2.2(CI 1.1-4.5;P=0.025)。
- Dublin 研究(n=52)风险比 2.2(CI 1.1-4.3),Barcelona 研究(n=35)风险比 2.8(CI 0.98-5.5)。
- 合并队列(n=196)发生 37 例复发性卒中(PET 前 29 例,PET 后 8 例)。
- 合并队列全校正任何复发性卒中风险比 2.19(CI 1.41-3.39;P<0.001),PET 后复发性卒中风险比 4.57(CI 1.5-13.96;P=0.008)。
- 复发性卒中风险随 SUVmax 四分位数升高而增加(log-rank P=0.003)。
关键数值与推荐
- 18F-FDG 摄取以轴位最热层面的最大标准化摄取值(SUVmax)表示。
- 任何复发性卒中 ROC 曲线下面积 0.70(CI 0.59-0.78),PET 后复发性卒中 0.80(CI 0.64-0.96)。
临床怎么用
- 18F-FDG PET 可能改善颈动脉血运重建的患者选择。
- 结果提示抗炎药物可能对卒中后血管预防有益。
局限性
- 需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Plaque inflammation contributes to stroke and coronary events. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) identifies plaque inflammation-related metabolism. Almost no prospective data exist on the relationship of carotid 18F-FDG uptake and early recurrent stroke. Methods- We did a multicenter prospective cohort study BIOVASC (Biomarkers/Imaging Vulnerable Atherosclerosis in Symptomatic Carotid disease) of patients with carotid stenosis and recent stroke/transient ischemic attack with 90-day follow-up. On coregistered carotid 18F-FDG PET/computed tomography angiography, 18F-FDG uptake was expressed as maximum standardized uptake value (SUVmax) in the axial single hottest slice. We then conducted a systematic review of similar studies and pooled unpublished individual-patient data with 2 highly similar independent studies (Dublin and Barcelona). We analyzed the association of SUVmax with all recurrent nonprocedural stroke (before and after PET) and with recurrent stroke after PET only. Results- In BIOVASC (n=109, 14 recurrent strokes), after adjustment (for age, sex, stenosis severity, antiplatelets, statins, diabetes mellitus, hypertension, and smoking), the hazard ratio for recurrent stroke per 1 g/mL SUVmax was 2.2 (CI, 1.1-4.5; P=0.025). Findings were consistent in the independent Dublin (n=52, hazard ratio, 2.2; CI, 1.1-4.3) and Barcelona studies (n=35, hazard ratio, 2.8; CI, 0.98-5.5). In the pooled cohort (n=196), 37 recurrent strokes occurred (29 before and 8 after PET). Plaque SUVmax was higher in patients with all recurrence ( P<0.0001) and post-PET recurrence ( P=0.009). The fully adjusted hazard ratio of any recurrent stroke was 2.19 (CI, 1.41-3.39; P<0.001) and for post-PET recurrent stroke was 4.57 (CI, 1.5-13.96; P=0.008). Recurrent stroke risk increased across SUVmax quartiles (log-rank P=0.003). The area under receiver operating curve for all recurrence was 0.70 (CI, 0.59-0.78) and for post-PET recurrence was 0.80 (CI, 0.64-0.96). Conclusions- Plaque inflammation-related 18F-FDG uptake independently predicted future recurrent stroke post-PET. Although further studies are needed, 18F-FDG PET may improve patient selection for carotid revascularization and suggest that anti-inflammatory agents may have benefit for poststroke vascular prevention.
引用
- Kelly PJ, Camps-Renom P, Giannotti N, et al. Carotid Plaque Inflammation Imaged by 18F-Fluorodeoxyglucose Positron Emission Tomography and Risk of Early Recurrent Stroke. Stroke. 2019. PMID: 31167623. doi:10.1161/STROKEAHA.119.025422
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。